Enalapril Response in Renovascular Hypertension
Yes, renovascular hypertension responds well to enalapril in most patients, but with critical caveats: 10-20% will develop unacceptable rises in serum creatinine (particularly with volume depletion or bilateral disease), and close monitoring of renal function is mandatory. 1
Blood Pressure Control Efficacy
Enalapril (an ACE inhibitor) is highly effective for blood pressure control in renovascular hypertension:
Moderate degrees of renovascular hypertension can most often be managed with medical therapy, particularly with agents that block the renin-angiotensin system like enalapril, as demonstrated by several prospective randomized trials 1
In clinical studies, enalapril successfully controlled blood pressure in 78-100% of renovascular hypertension patients when used alone or combined with hydrochlorothiazide 2, 3, 4, 5, 6
The enalapril/hydrochlorothiazide combination proved more effective than triple-drug therapy (hydrochlorothiazide/timolol/hydralazine) in one randomized trial, with all patients achieving excellent blood pressure control versus only 50% on triple therapy 6
Critical Renal Function Concerns
The major limitation is renal dysfunction risk:
10-20% of patients with renovascular disease will develop an unacceptable rise in serum creatinine during ACE inhibitor therapy, particularly with volume depletion 1
This risk is substantially higher in patients with:
- Bilateral renal artery stenosis (functional solitary kidney)
- Stenosis to a solitary functioning kidney
- Pre-existing renal insufficiency
- Concurrent diuretic use causing volume depletion
In one study, 4 of 16 patients (25%) experienced compromised renal function, requiring enalapril cessation in 2 cases 4
The FDA label confirms that increases in creatinine are "more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis" 7
Monitoring Protocol
Mandatory close monitoring during enalapril initiation:
- Check serum creatinine before starting and within 1-2 weeks after initiation
- A rise in creatinine >20 μmol/L (>0.23 mg/dL) should prompt immediate evaluation 8
- Monitor for signs of "flash pulmonary edema" (circulatory congestion), which carries high mortality risk 1
- Ensure adequate volume status before and during therapy
Long-Term Considerations
The long-term renal effects remain somewhat uncertain:
- Short-term studies (6-8 weeks) showed no adverse effects on glomerular filtration rate or renal blood flow in most patients 2, 3
- However, longer follow-up (6-18 months) revealed variable grades of GFR decrease in 3 of 5 patients, though the mechanism and relationship to enalapril remained unclear 2
- Large data registries indicate ACE inhibitor treatment in patients with identified renal artery stenosis confers a long-term mortality benefit 1
Clinical Decision Algorithm
Use enalapril in renovascular hypertension when:
- Unilateral renal artery stenosis with normal contralateral kidney
- Adequate baseline renal function (creatinine <1.5 mg/dL preferred)
- Patient is euvolemic (not volume depleted)
- Close monitoring is feasible
Exercise extreme caution or avoid when:
- Bilateral renal artery stenosis
- Stenosis to a solitary functioning kidney
- Baseline GFR ≤30 mL/min
- Volume depletion present
Most patients who experience creatinine rise during ACE inhibitor treatment can usually tolerate restarting the medication after successful revascularization 1, suggesting the renal dysfunction is hemodynamically mediated rather than intrinsic nephrotoxicity.
The current practice paradigm has shifted to optimizing antihypertensive drug therapy (including ACE inhibitors like enalapril) as the primary treatment for patients with identified renal artery stenosis before considering complex interventional strategies 1.